IAS 2011: HIV Treatment In Primary Infection: 48 Week Course Modestly Delays CD4 Drop
- Details
- Category: Primary/Acute HIV
- Published on Friday, 12 August 2011 00:00
- Written by Keith Alcorn
A 48-week course of antiretroviral treatment started within six months of becoming infected modestly delays the need for lifelong treatment, reported Sarah Fidler of Imperial College, London, at the 6th International AIDS Society Conference (IAS 2011) in Rome.
IAS 2011: Poor CD4 Cell Recovery after Starting HIV Treatment Should Be a Cause For Concern
- Details
- Category: HIV Disease Progression
- Published on Tuesday, 09 August 2011 00:00
- Written by Michael Carter
Patients whose CD4 cell count does not recover despite achieving virologic control with HIV therapy require continued medical attention, results of a large European study presented to the recent International AIDS Society conference (IAS 2011) in Rome show.
IAS 2011: Hormonal Contraceptive Use Increases Women’s Risk of Acquiring and Transmitting HIV
- Details
- Category: HIV Sexual Transmission
- Published on Friday, 05 August 2011 00:00
- Written by Roger Pebody
A two-year, seven-country study has concluded that women using hormonal contraceptives, particularly injectable forms, are at a greater risk both of acquiring HIV themselves and of passing it on to a male sexual partner.
IAS 2011: Maraviroc Improves Liver Fibrosis in HIV/Hepatitis C Coinfected Patients
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 09 August 2011 00:00
- Written by Michael Carter
Treatment with maraviroc is associated with the regression of liver fibrosis in HIV-positive patients co-infected with hepatitis C, a small randomised study presented to the Sixth International AIDS Society conference (IAS 2011) in Rome shows.
IAS 2011: Inflammation Markers Linked to Liver Disease, Death in HIV/HBV and HIV/HCV Coinfection
- Details
- Category: IAS 2011
- Published on Friday, 05 August 2011 00:00
- Written by Liz Highleyman
Various blood biomarkers associated with immune activation and inflammation predicted liver flares, fibrosis progression, and death among HIV positive people coinfected with hepatitis B or C, according to 2 studies presented last month at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome.
More Articles...
- Expert Overview from IAS 2011 [VIDEO]
- IAS 2011: HIV NNRTI Rilpivirine Effective and Well-Tolerated at 2 Years
- IAS 2011: People with HIV Have Double Risk for Non-Melanoma Skin Cancers
- IAS 2011: Anti-Herpes Drugs Reduce HIV Viral Load, Slow Disease Progression
- IAS 2011: Final iPrEX Analysis Confirms PrEP Effectiveness for Gay Men
- IAS 2011: iPrEx Shows PrEP is Durable [VIDEO]
- IAS 2011: New Integrase Inhibitor Dolutegravir Looks Potent and Well-tolerated
- IAS 2011: Raltegravir Still Effective at 5 Years
- IAS 2011: Doubt Remains if HIV Therapy Increases the Risk of Fragility Fractures
- IAS 2011: HIV PrEP Effective for Heterosexuals, Discordant Couples
Web Design and Development by